CRVS
Corvus Pharmaceuticals, Inc.7.94
-0.45-5.36%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
592.97MP/E (TTM)
-Basic EPS (TTM)
-0.54Dividend Yield
0%Recent Filings
8-K
Soquelitinib trials advance
Corvus Pharmaceuticals completed enrollment in soquelitinib's atopic dermatitis Phase 1 extension cohort 4 (200 mg BID, 8 weeks), with data due January 2026; Phase 2 trial starts early Q1 2026. Phase 3 PTCL trial enrolls steadily, final Phase 1/1b results hit ASH oral session. Cash hit $65.7M, funding into Q4 2026, while Q3 net loss narrowed to $10.2M from $40.2M. R&D ramped to $8.5M.
10-Q
Q3 FY2025 results
Corvus posted a Q3 operating loss of $10.6M, up 46% y/y from $7.3M (derived), driven by R&D expenses jumping to $8.5M from $5.2M on soquelitinib manufacturing and trials. Yet net loss narrowed sharply to $10.2M from $40.2M, thanks to no repeat of prior warrant liability charges. Cash and marketable securities stood at $65.7M, down from year-end amid $23.6M operating burn, offset by $35.7M warrant exercises; no debt. Warrant liability cleared post-exercise. Clinical burn accelerates. Going concern doubt flags funding needs by Q4 2026. Competition shadows lymphoma field.
8-K
Moore joins Corvus board
Corvus Pharmaceuticals appointed David Moore to its Board as a Class III director on October 2, 2025, with term through the 2028 annual meeting. He joins the Compensation and Nominating Committees. New board seat brings $35,000 annual retainer plus a 30,000-share option grant. Strengthens governance oversight.
8-K
Strong soquelitinib AD data
Corvus reported Q2 soquelitinib Phase 1 atopic dermatitis data showing cohort 3's 64.8% EASI reduction at day 28, beating prior cohorts' 54.6% and placebo's 34.4%, with itch relief by day 8. Cash swelled to $74.4M from $52.0M after $35.7M warrant exercises, funding ops into Q4 2026 despite $8.0M net loss. Trials advance swiftly.
10-Q
Q2 FY2025 results
Corvus Pharmaceuticals posted Q2 operating expenses of $10.3M, up 73% y/y (derived), driven by soquelitinib manufacturing and trials, while net loss narrowed to $8.0M from $4.3M y/y thanks to $2.0M warrant fair-value gain. Cash and equivalents hit $14.7M with marketable securities at $59.7M, totaling $74.4M liquidity after $35.7M warrant exercises; operating cash burn was $14.0M YTD. No debt. Warrant liability cleared. Clinical burn accelerates on PTCL Phase 3 and atopic dermatitis data. Competition in oncology immunology looms large.
ACRS
Aclaris Therapeutics, Inc.
3.21+0.04
CNTB
Connect Biopharma Holdings Limi
2.36+0.06
CRBP
Corbus Pharmaceuticals Holdings
8.66-0.82
CRIS
Curis, Inc.
1.18-0.01
CRNX
Crinetics Pharmaceuticals, Inc.
48.61-0.71
CUE
Cue Biopharma, Inc.
0.41-0.05
CVM
Cel-Sci Corporation
5.90-0.10
IMTX
Immatics N.V.
10.09+0.11
NUVB
Nuvation Bio Inc.
8.66+0.15
RCUS
Arcus Biosciences, Inc.
22.20+0.29